Company intelligence / Profile preview

LUCA Science Inc.

Chuo-ku, Tokyo, Japan

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

LUCA Science has demonstrated that administration of isolated wild-type mitochondria extended lifespan, improved neurological function, and enhanced energy expenditure in Leigh Syndrome-affected mice. Their human Mitochondria Organelle Complex Q (MRC-Q) also ameliorated symptoms of Leigh Syndrome in mouse models[5].

Therapeutic areas: Rare DiseasesCardiovascularNeurologyMetabolic Disorders
Modalities: Mitochondrial therapy
Industry: Biotech

Drug pipeline

1 asset

Mitochondrial therapeutic

Pre-clinical

Indications: Ischemia-reperfusion injury, Leigh Syndrome

Partnerships

Kyowa Kirin Co., Ltd. (collaboration to co-develop mitochondrial therapy for rare genetic diseases)[1]

Beyond the preview

Go deeper on LUCA Science Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LUCA Science Inc..

Explore the full profile